The ~$13.6M net proceeds extend cash runway only into Q4 2026, and the company explicitly states it will need substantial additional funding. The Phase 2 miss and going-concern warning make this a distressed financing. Watch for further dilution — the shelf still has ~$385M remaining capacity, and the company will likely need another capital raise before year-end. The 30-day lock-up on officers/directors expires in early August, which could add selling pressure.
Price Chart
Executive Summary
Elicio Therapeutics is raising approximately $13.6 million in net proceeds through a registered direct offering of 4,380,313 shares of common stock at $3.43 per share, a ~12% discount to the prior close of $3.91. The company's lead Phase 2 trial (AMPLIFY-7P) failed its primary endpoint, and cash runway extends only into Q4 2026, making this dilutive offering a necessary but negative signal for existing shareholders.
Key Facts
- Offering of 4,380,313 shares at $3.43 per share, a ~12% discount to the $3.91 prior close.
- Gross proceeds of approximately $15.0 million; net proceeds of ~$13.6 million after fees and expenses.
- Shares outstanding will increase from 18,639,895 to 23,020,208, a ~23.5% dilution.
- New investors face immediate dilution of $2.90 per share (offering price of $3.43 vs. as-adjusted net tangible book value of $0.53).
- Net tangible book value was negative $(0.08) per share as of March 31, 2026.
- Cash runway extends only into Q4 2026; the company explicitly states it will need substantial additional funding.
- Lead Phase 2 trial (AMPLIFY-7P) failed its primary DFS endpoint in the ITT population.
- Auditor's report contains a going concern explanatory paragraph.
- Offering priced at a ~12% discount to the $3.91 prior close.
Financial Impact
Gross proceeds of ~$15.0M; net proceeds ~$13.6M. Dilution of ~23.5% to existing shareholders. Immediate dilution of $2.90 per share for new investors.
Risk Factors
- Cash runway only into Q4 2026; substantial additional funding required.
- Phase 2 AMPLIFY-7P trial failed its primary DFS endpoint; Phase 3 strategy is unproven and subject to financing.
- Immediate dilution of ~23.5% to existing shareholders; $2.90 per share dilution for new investors.
- Going concern warning in auditor's report; risk of bankruptcy if further capital cannot be raised.
- Massive overhang from 3.6M common warrants, 2.6M pre-funded warrants, and 3.2M ATM shares sold since March 31.
- 30-day lock-up on officers/directors expires in early August, which could add selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-080106 |
| Document: 0001104659-26-080106-index-headers.html | 0001104659-26-080106 |
| Document: 0001104659-26-080106-index.html | 0001104659-26-080106 |
| Document: 0001104659-26-080106.txt | 0001104659-26-080106 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | DEF 14A | $1.88 | awaiting T+60 | — | $1.70 (−9.57%) |
Sep 22, 2026 4w ago | Institutional Cluster | $1.87 | awaiting T+60 | — | $1.70 (−9.09%) |
Jul 2, 2026 16w ago | 424B5 | $3.22 $1.88 | ▲ +41.61% | ▲ +44.62% | $1.70 (+47.20%) |
Jul 2, 2026 16w ago | 8-K | $3.22 $1.88 | ▲ +41.61% | ▲ +44.62% | $1.70 (+47.20%) |
Jun 24, 2026 17w ago | 8-K | $3.75 $1.89 | ▼ −49.60% | ▼ −53.33% | $1.70 (−54.67%) |
Jun 17, 2026 18w ago | 8-K | $4.71 $2.05 | ▼ −56.48% | ▼ −59.62% | $1.70 (−63.91%) |
May 11, 2026 24w ago | 8-K | $10.55 $3.14 | ▼ −70.24% | ▼ −74.62% | $1.70 (−83.89%) |
Mar 17, 2026 32w ago | EFFECT | $12.18 $14.20 | ▲ +16.58% | ▲ +6.72% | $1.70 (−86.04%) |
Mar 12, 2026 32w ago | Press Release | $12.20 $13.55 | ▲ +11.07% | ▼ −0.55% | $1.70 (−86.07%) |
Mar 2, 2026 34w ago | S-3/A | $12.50 $10.77 | ▲ +13.84% | ▲ +24.16% | $1.70 (+86.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers